奥西替尼治疗EGFR突变肺腺癌脑转移的效果及对预后影响

Efficacy and Prognosis of Osimertinib in the Treatment of Brain Metastases from EGFR-mutant Lung Adenocarcinoma

目的:初步探讨奥西替尼治疗表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变肺腺癌脑转移的效果及对预后影响。方法:将2017年6月-2019年12月在本院就诊的60例EGFR突变肺腺癌脑转移患者随机分为对照组和奥西替尼组,对照组进行放射疗法,奥西替尼组在对照组的治疗基础上口服奥西替尼,比较并分析两组近期疗效、长期疗效、不良反应情况。结果:奥西替尼组RR为70.00%,高于对照组的43.33%(P<0.05);奥西替尼组1年生存率为50.00%,高于对照组的27.59%,奥西替尼组1年的无进展生存时间为10个月,对照组为6个月(P<0.05);奥西替尼组腹泻和皮疹的不良反应发病率高于对照组(P<0.05)。结论:奥西替尼具有很好的临床疗效,可以明显提高有效率及生存率,不良反应发生率较低,并大大延长生存时间。

Objective:To preliminarily explore the efficacy and prognosis of Osimertinib in the treatment of brain metastases from EGFR-mutant lung adenocarcinoma.Method:Sixty patients with EGFR-mutant lung adenocarcinoma brain metastases who were treated in our hospital from June 2017 to December 2019 were randomly divided into the control group and the Osimertinib group.The control group received radiotherapy,and the Osimertinib group was taken orally Osimertinib on the basis of the control group treatment,and the short-term curative effect,long-term curative effect,and adverse reactions of the two groups were compared and analyzed.Result:The RR in the Osimertinib group was 70.00%,which was higher than 43.33%in the control group(P<0.05);the 1-year survival rate in the Osimertinib group was 46.67%,which was higher than 26.67%in the control group.The progression survival time was 10 months,and the control group was 6 months(P<0.05);the incidence of adverse reactions of diarrhea and rash in the Osimertinib group was higher than that in the control group(P<0.05).Conclusion:Osimertinib has a good clinical effect,can significantly improve the effective rate and survival rate,the incidence of adverse reactions is low,and greatly extend the survival time.